日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Selective Pharmaceutical Inhibition of PARP14 Mitigates Allergen-Induced IgE and Mucus Overproduction in a Mouse Model of Pulmonary Allergic Response

选择性药物抑制 PARP14 可减轻小鼠肺部过敏反应模型中过敏原诱导的 IgE 和粘液过量产生

Alex M Eddie, Kevin W Chen, Laurie B Schenkel, Kerren K Swinger, Jennifer R Molina, Kaiko Kunii, Ariel L Raybuck, Heike Keilhack, Katherine N Gibson-Corley, Mario Niepel, R Stokes Peebles, Mark R Boothby, Sung Hoon Cho

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

通过抑制 EZH2 选择性杀死 SMARCA2 和 SMARCA4 缺陷型卵巢小细胞癌、高钙血症型细胞:体外和体内临床前模型

Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

他泽司他抑制 EZH2 导致 DLBCL 对 B 细胞活化信号的依赖性改变

Dorothy Brach, Danielle Johnston-Blackwell, Allison Drew, Trupti Lingaraj, Vinny Motwani, Natalie M Warholic, Igor Feldman, Christopher Plescia, Jesse J Smith, Robert A Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K Knutson, Scott A Ribich, Alejandra Raimondi, Michael J Thomenius

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

儿科临床前测试计划对新型 EZH2 抑制剂他泽司他 (EPZ-6438) 进行初步测试(第 1 阶段)

Raushan T Kurmasheva, Melissa Sammons, Edward Favours, Jianwrong Wu, Dias Kurmashev, Katherine Cosmopoulos, Heike Keilhack, Christine R Klaus, Peter J Houghton, Malcolm A Smith

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

EZH2 抑制在人类滑膜肉瘤模型中诱导抗肿瘤活性的临床前证据

Satoshi Kawano, Alexandra R Grassian, Masumi Tsuda, Sarah K Knutson, Natalie M Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M Pollock, Jesse S Smith, Kevin K Kuntz, Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A Copeland, Shinya Tanaka, Heike Keilhack

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas

EZH2 抑制剂和糖皮质激素受体激动剂在生发中心非霍奇金淋巴瘤模型中的协同抗肿瘤活性

Sarah K Knutson, Natalie M Warholic, L Danielle Johnston, Christine R Klaus, Tim J Wigle, Dorothy Iwanowicz, Bruce A Littlefield, Margaret Porter-Scott, Jesse J Smith, Mikel P Moyer, Robert A Copeland, Roy M Pollock, Kevin W Kuntz, Alejandra Raimondi, Heike Keilhack

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

通过抑制甲基转移酶 EZH2 实现基因改变的恶性横纹肌样瘤的持久肿瘤消退

Sarah K Knutson, Natalie M Warholic, Tim J Wigle, Christine R Klaus, Christina J Allain, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P Moyer, Robert A Copeland, Victoria M Richon, Roy M Pollock, Kevin W Kuntz, Heike Keilhack

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors

mTOR 通过 AKT 非依赖性机制激活的证据为使用 mTOR 和 AKT 抑制剂联合治疗 PTEN 缺陷型前列腺肿瘤提供了支持

Weisheng Zhang, Brian B Haines, Clay Efferson, Joe Zhu, Chris Ware, Kaiko Kunii, Jennifer Tammam, Minilik Angagaw, Marlene C Hinton, Heike Keilhack, Cloud P Paweletz, Theresa Zhang, Chris Winter, Sriram Sathyanarayanan, Jonathan Cheng, Leigh Zawel, Stephen Fawell, Gary Gilliland, Pradip K Majumder

Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor

癌细胞中 PDK1 的基因和药理抑制:选择性变构激酶抑制剂的表征

Kumiko Nagashima, Stuart D Shumway, Sriram Sathyanarayanan, Albert H Chen, Brian Dolinski, Youyuan Xu, Heike Keilhack, Thi Nguyen, Maciej Wiznerowicz, Lixia Li, Bart A Lutterbach, An Chi, Cloud Paweletz, Timothy Allison, Youwei Yan, Sanjeev K Munshi, Anke Klippel, Manfred Kraus, Ekaterina V Bobkova,